Comparative Pharmacology
Head-to-head clinical analysis: AMBIEN versus PLACIDYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBIEN versus PLACIDYL.
AMBIEN vs PLACIDYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA. Binds selectively to the alpha-1 subunit, producing sedative, hypnotic, and anxiolytic effects.
Ethchlorvynol is a sedative-hypnotic that depresses the central nervous system at the level of the brainstem and reticular formation, potentiating GABAergic inhibition. Its exact molecular mechanism is not fully defined.
5-10 mg orally once daily at bedtime, maximum 10 mg/day.
500 mg to 1000 mg orally at bedtime, as a hypnotic. Usual dose is 500 mg to 750 mg. Maximum dose 1000 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 2.6 hours (range 1.4–4.5 hours). In elderly patients, half-life may be prolonged to about 2.9 hours. In patients with hepatic cirrhosis, half-life is significantly increased (up to 9.8 hours).
Terminal elimination half-life is approximately 24 hours (range 10-40 hours), with prolonged elimination in hepatic impairment and overdose due to saturation of metabolism.
Primarily renal excretion: approximately 56% of the dose is recovered in urine as metabolites (including 5% unchanged drug). Fecal excretion accounts for about 34% of the dose. Small amounts are excreted in bile.
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for 30-40% of metabolites, with enterohepatic recycling.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic